$0.860
-0.005 (-0.58%)收盤時
BGMS 獲利能力與利潤率
Evaluating the bottom line, Bio Green Med Solution Inc maintains a gross margin of 23.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -124.40%, while the net margin is -120.54%. These profitability ratios, combined with a Return on Equity (ROE) of -171.64%, provide a clear picture of how effectively BGMS converts its operational activities into shareholder value.
BGMS 同業比較
In the context of the broader market, BGMS competes directly with industry leaders such as CNSP and ACXP. With a market capitalization of $5.69M, it holds a significant position in the sector. When comparing efficiency, BGMS's gross margin of 23.51% stands against CNSP's N/A and ACXP's N/A. Such benchmarking helps identify whether Bio Green Med Solution Inc is trading at a premium or discount relative to its financial performance.
Bio Green Med Solution Inc 財務表現
Bio Green Med Solution has shown volatility in its financial performance, with total revenue of $666,000 in Q4 2025 and a net income loss of -611,000 in the same quarter. The gross margin has fluctuated, reaching 23.51% in Q2 2026, but the overall trend indicates financial instability.
Financials
相關文章
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。